""We expect this restructuring will have a meaningful impact on our 2026 operating expenses and position Geron to meet the needs of patients," Semerjian added. "I want to express my gratitude to the employees that will be impacted in this restructuring. Your contributions over the years have made a positive difference in the lives of the people we endeavor each day to assist.""
""Geron's flagship drug is called Rytelo, a blood cancer treatment for adults with anemia. The company was founded in 1990 and has boasted scientific advisers who won a Nobel Prize for their work on telomerase, an enzyme that helps cancer cells survive and proliferate. In June 2024, Rytelo became the company's first effort approved for commercial sale by the Food and Drug Administration, and the first FDA-approved drug for inhibiting telomerase.""
""Rytelo is reaching patents - Geron reported more than four times the revenue in the first nine months of 2025 than the same stretch of 2024 - but not yet enough to make the company profitable. Investor faith in Geron tumbled after a high around the time of the FDA approval: The company's valuation topped $2.5 billion late last year and now sits around $860 million.""
Geron will reduce its workforce by about 85 employees, roughly one-third of its approximately 260-person staff, as part of a restructuring described as fiscally prudent. The restructuring is expected to meaningfully lower 2026 operating expenses and position the company to meet patient needs. Rytelo, a blood cancer treatment for adults with anemia, received FDA approval in June 2024 as the first telomerase-inhibiting drug and is Geron's first commercial product. Revenue in the first nine months of 2025 exceeded the same period in 2024 by more than fourfold, but the company remains unprofitable and its market valuation has fallen substantially.
Read at SFGATE
Unable to calculate read time
Collection
[
|
...
]